- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Obicetrapib, Placebo
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 199
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 161 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 49
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension, Hyperlipidemias
- Interventions
- Penn Med Healthy Heart Program
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1,980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- ASCVD, Diabetes
- Interventions
- SMS (Initial Outreach), Secure Portal Message (Initial Outreach), Non-secure Email (Initial Outreach), SMS (Follow-up for Non-responders), Secure Portal Message (Follow-up for Non-responders), Non-secure Email (Follow-up for Non-responders)
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pleasant Hill, California
- Conditions
- Cardiovascular Disease
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 101
- States / cities
- Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
- Conditions
- Lipoprotein Disorder
- Interventions
- Kylo-11 or matched placebo
- Drug
- Lead sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • Santa Maria, California + 13 more
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
- Interventions
- Low-dose Colchicine at 0.5mg daily, Usual Care
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
- Interventions
- ABP-745 Dose A, Placebo, ABP-745 Dose B, ABP-745 Dose C
- Drug
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • San Diego, California • Torrance, California + 1 more
- Conditions
- Cardiovascular Disease
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 357
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Placebo, Olpasiran
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 7,297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more
- Conditions
- Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
- Interventions
- TQJ230, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
- Conditions
- Lipoprotein Disorder
- Interventions
- DII235, Saline
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 33 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
- Interventions
- AI-Detected CAC Notification and Care Facilitation
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 120,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Pleasanton, California • Stanford, California + 3 more
- Conditions
- Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 285,327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement, Vascular Function Testing
- Diagnostic Test
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Type 2 Diabetes, Overweight, ASCVD
- Interventions
- Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60,000 participants
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
- Interventions
- Muvalaplin, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more
- Conditions
- Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- End Stage Kidney Disease
- Interventions
- CSL300, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 166
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- ASCVD, Coronary Artery Calcification
- Interventions
- Notification of patients and clinicians
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Interventions
- Pelacarsen, Placebo, Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- Placebo, Obicetrapib
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 69
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Interventions
- VERVE-102, Placebo
- Drug
- Lead sponsor
- Verve Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- DeSoto, Texas
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- bempedoic acid
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio